PhRMA submission to the 2019 National Trade Estimate Report urges action to protect U.S. biopharmaceutical innovation


International trade is critical to delivering life-saving and life-enhancing medicines in the global economy, which is why PhRMA addresses several discriminatory foreign government practices in its 2019 National Trade Estimate (NTE) Report submission to the Office of the United States Trade Representative (USTR). Trade practices that violate international obligations or otherwise undermine innovation and access to medicines threaten the biopharmaceutical industry’s ability to produce new treatments and cures. In so doing, such practices jeopardize high-value American jobs, the global competitiveness of several of the most innovative U.S. companies, and significant investment, research, development, and manufacturing in the United States.